341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers
The Readout Loud
00:00
Exploring the Viability of AI in Drug Discovery
This chapter examines the bold claims of startups Absci and Generate Biomedicines about their AI-driven drug design methods, focusing on de novo drug creation. It highlights the skepticism from industry experts regarding the practicality of developing drugs from scratch and the computational challenges faced in drug discovery.
Transcript
Play full episode
